Progenics Pharmaceuticals, Inc.
Records under this name other than the patents Progenics Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
Back to Progenics Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D714,932 | Automatic Injection Device Formerly held In force · High confidence | In force | High confidence | |
| US D715,422 | Automatic Injection Device Formerly held In force · High confidence | In force | High confidence | |
| US 11,571,383 | Concentrated Protein Formulations and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 9,956,165 | Concentrated Protein Formulations and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,973,486 | Systems and Methods for Rapid Neural Network-Based Image Segmentation and Radiopharmaceutical Uptake Determination Formerly held In force · High confidence | In force | High confidence | |
| US 12,417,533 | Systems and Methods for Artificial Intelligence-Based Image Analysis for Cancer Assessment Formerly held In force · High confidence | In force | High confidence | |
| US 11,900,597 | Systems and Methods for Artificial Intelligence-Based Image Analysis for Cancer Assessment Formerly held In force · High confidence | In force | High confidence | |
| US 11,937,962 | Systems and Methods for Automated and Interactive Analysis of Bone Scan Images for Detection of Metastases Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,414,748 | Systems and Methods for Automated and Interactive Analysis of Bone Scan Images for Detection of Metastases Formerly held In force · Low confidence | In force | Low confidence | |
| US 8,821,877 | Methods for Inhibiting HIV-1 Replication Involving the Administration of an ANTI-CCR5 Receptor Monoclonal Antibody and Small Molecule CCR5 Receptor Antagonist. Formerly held Term ended Term ended Jul 21, 2026 · High confidence | Term ended | Term ended Jul 21, 2026 | High confidence |